Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study of Treprostinil Administered Via a Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

NCT07923526 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07923526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study of Treprostinil Administered Via a Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Lead sponsor
United Therapeutics
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
March 31, 2027
Completion date
September 30, 2034
Enrollment
400 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension associated with chronic obstructive pulmonary disease

Arms

As registered; 1 arm.

  • treprostinil SMI Experimentaltreprostinil SMI (treprostinil inhalation spray)

    Inhaled treprostinil administered via a SMI at concentrations of 1.34, 2.68, 4.02, 5.36 and 6.70 mg/mL

Primary endpoints

Registered primary outcome measures; 9 primary.

  • Incidence of adverse events (AEs) and serious AEs (SAEs) Up to 7.5 years

    Number and type of AEs and SAEs observed in participants during and after use of treprostinil SMI.

  • Change in Forced Expiratory Volume in One Second (FEV1) as % predicted Up to 7.5 years

    FEV1 is a standard indicator of lung function and measures the maximal amount of air forcefully exhaled in 1 second.

  • Change in Forced Vital Capacity (FVC) in mL Up to 7.5 years

    FVC is a standard indicator of lung function and measures the amount of air a person can forcefully and quickly exhale after taking a deep breath.

  • Change in FEV1/FVC ratio Up to 7.5 years

    The FEV1/FVC ratio measures how much air is exhaled in one second compared to a full breath. This helps determine if the lung condition is restrictive or obstructive and its severity.

  • Change in Total Lung Capacity (TLC) in mL Up to 7.5 years

    TLC is a standard indicator of lung function and measures the maximum volume of lung capacity after very deep inhalation.

+4 more primary endpoints

Lead sponsor's other trials

United Therapeutics, most recent start first.

Similar trials

Same condition (Hypertension, Pulmonary) and phase, most recent start first.